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Introduction
Esophageal squamous cell carcinoma (ESCC) is the sixth most common cause of  cancer death worldwide 
(1, 2). Endemic ESCC occurs in specific regions of  the world including 2 high-risk belts in central Asia and 
sub-Saharan Africa (SSA), where the incidence is more than 20-fold higher than in Western countries. In 
Malawi, a country of  nearly 17 million people in southern Africa, ESCC is the third most common cancer, 
accounting for 12% of  all malignancies (3). At Kamuzu Central Hospital in Lilongwe, Malawi, ESCC was 
diagnosed in 27% of  esophagogastroduodenoscopies performed (4). ESCC patients in SSA are typically 
diagnosed at advanced stages with substantial dysphagia and malnutrition, and suffer poor outcomes (5).
The underlying reasons for high ESCC incidence in SSA remain unclear. While tobacco exposure and alco-
hol are considered the main risk factors in Western countries, they are not major factors in high-incidence areas, 
and in most studies greater than 60% of cases are nonsmokers (6). The high incidence of several cancers in SSA 
including Kaposi’s sarcoma, hepatocellular carcinoma, Burkitt’s lymphoma, and cervical cancer are known 
to be secondary to the oncogenic viruses human herpesvirus 8 (HHV8), hepatitis B virus (HBV), Epstein-
Barr virus (EBV), and human papillomavirus (HPV), respectively. However, evidence for a novel or established 
oncovirus etiology in ESCC has yet to be identified. Prior work in Brazil, China, and Iran has suggested that 
ingestion of polycyclic aromatic hydrocarbons through traditional teas and other sources, thermal injury from 
scalding hot beverages, and dietary selenium deficiency may be potential etiologic contributors (7–11). How-
ever, definitive studies examining these and other risk factors in SSA have not been performed. Recent studies 
suggest that ESCC is more common in rural areas of Malawi where people are more likely to use wood for 
cooking, grow their own maize and store it in sacks at home, and use untreated water sources (4, 6).
Esophageal squamous cell carcinoma (ESCC) is endemic in regions of sub-Saharan Africa (SSA), 
where it is the third most common cancer. Here, we describe whole-exome tumor/normal 
sequencing and RNA transcriptomic analysis of 59 patients with ESCC in Malawi. We observed 
similar genetic aberrations as reported in Asian and North American cohorts, including mutations of 
TP53, CDKN2A, NFE2L2, CHEK2, NOTCH1, FAT1, and FBXW7. Analyses for nonhuman sequences did 
not reveal evidence for infection with HPV or other occult pathogens. Mutational signature analysis 
revealed common signatures associated with aging, cytidine deaminase activity (APOBEC), and a 
third signature of unknown origin, but signatures of inhaled tobacco use, aflatoxin and mismatch 
repair were notably absent. Based on RNA expression analysis, ESCC could be divided into 3 distinct 
subtypes, which were distinguished by their expression of cell cycle and neural transcripts. This 
study demonstrates discrete subtypes of ESCC in SSA, and suggests that the endemic nature of this 
disease reflects exposure to a carcinogen other than tobacco and oncogenic viruses.
While the Cancer Genome Atlas (TCGA) and related efforts have com-
prehensively analyzed the most common malignancies in Western coun-
tries, ESCC has been relatively understudied. While adenocarcinoma of the 
proximal stomach and esophagus is becoming more common in the United 
States and Europe, the incidence of  ESCC in Western nations has been in 
decline for decades (12, 13). Moreover, in the United States, ESCC is gener-
ally treated with neoadjuvant chemoradiotherapy, making the acquisition of  
pristine tumor tissue for comprehensive molecular analysis challenging. In 2 
other endemic regions, China and Japan, molecular studies have described the 
mutational landscape for ESCC in those countries (14–17). These analyses 
demonstrate frequent mutations in genes associated with other squamous can-
cers, including TP53, RB1, CDKN2A, PIK3CA, NOTCH1, and NFE2L2, as well 
as other potentially novel cancer-associated genes and histone modifier genes.
Unlike higher-resource settings, molecular biology approaches have 
rarely been applied to cancer in SSA. Throughout the region, there is lim-
ited pathology infrastructure, tissue procurement capability, and laboratory 
capacity to conduct genomic studies, as well as legitimate cultural and regu-
latory sensitivities regarding germline and somatic genomic research and 
transfer of  biologic specimens outside SSA. For ESCC, obtaining tumor 
specimens is especially challenging in settings with scarce endoscopy and 
thoracic surgery facilities. In Malawi, ESCC patients often do not undergo 
endoscopy or biopsy even when services are possible, due to clinicians’ sense 
of  futility when palliative stenting cannot be simultaneously performed, in a 
setting where stents are costly and typically unavailable.
Given the high incidence of  ESCC in SSA and the marked differences in 
the epidemiology of  ESCC in the West and Asia versus SSA, we undertook a dedicated analysis of  African 
tumors. To that end, 59 untreated ESCCs and matched normal pairs were analyzed from consenting Mala-
wian patients with ESCC, participating in a case-control study conducted at 2 national teaching hospitals 
in Lilongwe and Blantyre from 2011 to early 2013. Whole-exome DNA sequencing was performed on 
tumor and paired normal DNA, as well as whole-transcriptome RNA sequencing. Somatic mutations and 
copy number events were identified using approaches developed for TCGA (18). This analysis provides a 
comprehensive molecular evaluation of  ESCC, an understudied and highly lethal cancer that poses a sig-
nificant global public health burden.
Results
Description of  the patient cohort. 59 patients with ESCC participating in a case-control study at Kamuzu Cen-
tral Hospital, Lilongwe, Malawi and Queen Elizabeth Central Hospital, Blantyre, Malawi were enrolled in 
this study throughout 2011 and 2012. Potential participants were initially identified by clinical symptoms 
including dysphagia, odynophagia, hematemesis, and weight loss. ESCC diagnosis was confirmed by histo-
pathological sections after endoscopic biopsy or rarely surgical resection. All pathology underwent central 
re-review at the University of  North Carolina. Patients over 18 years of  age and willing to participate in 
this study provided written informed consent in their native language and had matched normal tissue taken 
concurrently at time of  biopsy or resection. Human studies approval was given by the Malawi National 
Health Sciences Research Committee and the University of  North Carolina Internal Review Board.
The study population included 27 males (46%) and 31 females (53%) (Table 1). In accord with the age 
distribution of  ESCC in SSA, this cohort was younger than cohorts in other continents, with the average 
age being 56 (range, 24–93) years and with 17 (29%) patients younger than 45 years old. Life expectancy 
in Malawi during the study period was approximately 55 years with 5% of  the population aged 60 years or 
older, suggesting that our ESCC cohort was older than the Malawi general population (19). Roughly 18% 
of  the Malawian population reports tobacco use including local cigarettes and Chingambwe (20), a chewed 
local tobacco, whereas 41% (24 of  59) of  the ESCC cohort reported tobacco use, suggesting a modest 
enrichment for tobacco users in this population, but the majority (56%) of  the cohort were never smokers. 
Of  patients with known HIV status, 10 (17%) of  the ESCC population were HIV+, which is slightly higher 
than the 11% population prevalence of  HIV during the study period (21). Cooking method and maize 
Table 1. Patient characteristics and demographics
Feature Category Malawi cohort, n = 59
Age (years) Mean 56
Range 24–93
Sex [n (%)] Male 27 (45.8)
Female 31 (52.5)
Unknown 1 (1.7)





Alcohol [n (%)] Yes 14 (23.7)
No 18 (30.5)
Unknown 27 (45.8)









flour type, both found to correlate with ESCC in this population (6), are indicated in Figure 1. Maize is 
the dietary staple of  Malawi and is processed in various ways. M’gaiwa is milled whole-grain maize, while 
gramil is dehulled, then milled. White maize is dehulled, soaked, washed, dried, and then milled, and likely 
contains the fewest contaminants of  the 3 flours.
Figure 1. Summary of patient characteristics and somatic point mutations. Each column represents 1 of 59 patient samples and columns are ordered based 
on RNA subtype (see Figure 4). The frequency of synonymous and nonsynonymous mutations per Mb sequenced (log scale) are stacked and shown at the 
top of the figure. Clinical and environmental characteristics of each sample are displayed in a matrix in the center of the figure, where each row is a single 
characteristic. Somatic single-nucleotide polymorphisms and copy number variations of each sample are displayed in a matrix in the bottom of the figure, 
where each row is a single mutated gene ordered top-to-bottom by decreasing percentage of the cohort with mutations in a given gene. Each mutation type 
is color coded and samples with 2 or more mutation types per gene are indicated by 2 or more colors. Percentage of the cohort with mutations in a given 
gene are shown in the bottom right of the figure.
Mutations and copy number events of  the tumors. We 
sequenced the exomes of  59 untreated ESCCs and matched 
normal pairs at a mean sequencing coverage of  85×, with 
97% of  targeted bases above 30× coverage. We simultaneous-
ly performed RNAseq on these same 59 tumors at an average 
of  150 million reads per sample. Through a combined anal-
ysis of  both RNA and DNA sequencing (22) we identified 
between less than 0.1 and 20 mutations per Mb of  sequenced 
target, with the exception of  1 sample, which exhibited muta-
tions of  genes involved in mismatch repair, demonstrating 
156 mutations per Mb (Figure 1). Mutations found at 5% or 
greater frequency are shown in Figure 1. In common with 
prior studies of  head and neck squamous cancers in the US (23) and ESCC in Asian populations (14–17), 
we found a significant enrichment of  inactivating or dominant-negative events of  the known tumor sup-
pressor genes TP53, CDKN2A, NOTCH1/3, FAT1/2/3/4, and FBXW7, as well as known activating events 
of  PIK3CA and NFE2L2. There was an enrichment of  mutations in genes encoding the chromatin-mod-
ifying enzymes KMT2D (MLL2), KMT2C (MLL3), and EP300. Mutations of  unclear biochemical effect 
were enriched in 2 other genes indirectly associated with squamous cancers (24, 25): JAG1, the NOTCH 
ligand, and SERPINB4, a granzyme inhibitor.
We queried for areas of  significant copy number change through genomic identification of  significant 
targets in cancer (GISTIC) analysis (Figure 2, with samples ordered as per Figure 1). We identified statisti-
cally enriched copy gains in TP63, MYC, CCND1, ERBB2, CCNE1, and MYCL1. Regions of  significant copy 
losses included 1q31, 3p, 5q, 9p21.3 (CDKN2A/CDKN2B), 10q25, and 21q22. Except for the deletions 
noted at 1q31, these regions of  amplification or deletion have been reported in Asian ESCCs and other 
squamous cancers (14–17). The 1q31 deletion was focused around CDC73, an established suppressor of  
parathyroid neoplasia. High-prevalence point mutations and copy number events are summarized in Figure 
1. The spectrum of  point mutations and copy number alterations (CNAs) did not significantly correlate
with measured epidemiologic exposures, patient clinical characteristics, or histologic features of  the disease 
(Figure 1). We observed an association of  CNAs with RNA subtype, with subtypes 1a and 2 having more
CNAs than subtype 1b (Figure 2, and see below). These data in aggregate suggest that the genes targeted
for point mutation and CNAs in African ESCCs are similar to those mutated in Asian ESCCs as well as
squamous malignancies of  the lung, head, and neck in Western populations.
Mutational spectral analysis and pathogen detection. As ESCC prevalence in some populations has been 
tied to carcinogen exposure, we sought to identify potential causes of  ESCC by mutation signature analysis 
(26, 27). We performed an analysis on this cohort of  59 ESCCs as well as on published exome data of  139 
ESCCs from a Chinese population (15). Stability analysis revealed 3 mutation signatures in SSA ESCCs 
(Figure 3A), as opposed to only 2 stable signatures in Chinese ESCCs (Figure 3B). Two signatures were 
consistent between SSA and Chinese cohorts, and matched previously reported patterns. The first shared 
signature, with abundant C to T transition mutations, is consistent with the age-associated signature seen 
in numerous types of  cancer. The second, with both C to G transversions and C to T transitions occurring 
at TCN trinucleotides, closely matches the APOBEC-associated cytidine deaminase signature, common in 
many malignancies (28).
In our SSA cohort, however, a third signature was observed that lacked overlap with prior signa-
ture analyses, including UV light, mismatch repair, DNA polymerase ε, aristolochic acid, aflatoxin, or 
BRCA1/2 mutation signatures. This third unknown signature was similar to the previously reported signa-
ture 29, which was associated with gingival buccal oral squamous cell carcinoma from individuals known 
to chew tobacco (29). It is characterized by an excess of  C to A transversions (predominantly at NCA trinu-
cleotides) and C to T transitions (predominantly at NCG trinucleotides). Concordant with these signature 
analyses of  whole-exome data, a dedicated analysis of  TP53 mutation hotspots did not identify known car-
cinogen-associated hotspot mutations (Table 2). Together, these results suggest that SSA ESCC is induced 
by mutations caused by age-associated spontaneous deamination of  5-methyl-cytosine, APOBEC-induced 
deamination of  cytosines that follow thymidines, and an occult mutagenic process that nonrandomly tar-
gets either cytosines or guanines to induce transitions and transversions. Importantly, we did not note 
evidence in either whole-exome analyses or TP53 mutations for excess mutagenic events related to several 
Table 2. TP53-specific analysis of hotspots at sites of known 
mutations among patients with TP53 SNPs
Carcinogen Hotspots Malawi cohort, n = 47
Smoking [n (%)] 157, 158, 273 3 (6.3)
Aristolochic acids [n (%)] 131, 209, 280 0 (0.0)
Aflatoxin B1 [n (%)] 249 0 (0.0)
UV radiation [n (%)] 248, 278 2 (4.3)
well-known environmental carcinogens (e.g., cigarette smoking, aflatoxin, mismatch repair). Additionally, 
we did not identify mutational signatures unique to groups exposed to previously reported potential local 
carcinogens (e.g., white maize flour, wood-fueled cooking) (6).
We considered the possibility that an occult infectious pathogen contributes to the etiology of  SSA 
ESCC. In particular, EBV has been associated with nonsquamous gastric cancer and Burkitt lymphoma 
(endemic in Malawi) and HPV has been associated with squamous malignancies of  the cervix, anus, and 
oropharynx, with prior reports in conflict regarding the role of  HPV in ESCC (30–33). We therefore looked 
for an occult pathogen in 2 ways: we searched RNAseq data for reads with homology to known viral tran-
scripts, and also assembled unmapped DNAseq reads and searched these unmapped contigs for homology 
to databases of  infectious agents. Using the former approach, we readily identified evidence of  chronic 
herpesviruses (e.g., EBV) and HIV in a small minority of  the samples. As these viruses are commonly 
found in circulating hematopoietic elements in humans, we believe these findings represent contamination 
of  the tumor biopsies with virus-containing lymphocytes rather than evidence for a tumor-promoting role 
of  these events. Consistent with this view, the read count for these viral sequences was low, and was seen 
in a proportion of  samples that was lower than the expected prevalence for the Malawian population (e.g., 
11% for HIV and greater than 90% for EBV) (21, 34–36). Importantly, neither the RNA nor DNA analysis 
suggested HPV infection, whereas these algorithms readily detect HPV sequences in HPV-infected cervical 
or oropharyngeal cancers. Further evidence for a lack of  HPV infection was the high frequency of  TP53 and 
CDKN2a inactivation, which are uncommon in HPV-induced tumors that express viral oncoproteins target-
ing the p53 and retinoblastoma (RB) pathways. Although these analyses cannot exclude the possibility that a 
minority of  SSA ESCCs are caused by an occult pathogen or by a pathogen that is not present in malignant 
cells (e.g., as with Helicobacter pylori and gastric cancer), these results suggest that SSA ESCC is not caused by 
an integrated (e.g., HPV) or episomal (e.g., EBV) tumor virus.
Figure 2. Summary of copy number alterations (CNAs). Genomic identification of significant targets in cancer (GISTIC) analysis of 59 esophageal squa-
mous cell carcinoma (ESCC) samples for significantly amplified or deleted regions. The genomic profile of the copy number data is displayed in a heat map 
in the center of the figure, where samples are ordered based on RNA subtype (see Figure 4). Significant amplifications are indicated on the left in red and 
deletions on the right in blue. The score at the bottom is the false discovery rate q value as calculated by GISTIC.
RNA expression analysis. We next considered whether samples in our cohort could be divided into gene 
expression subtypes. We first validated our RNAseq results by performing hierarchical clustering of  our data 
combined with TCGA RNAseq datasets from the PanCan analysis (18). All of  the ESCC samples clustered 
together, and nearest to squamous carcinomas of  the head, neck, and lung. Lung adenocarcinoma and other 
nonsquamous tumors were more distant from ESCC (Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/jci.insight.88755DS1). SSA ESCC, like other squamous tumors, 
was characterized by increased expression of  transcripts such as TP63, squamous cytokeratins (e.g., KRT5/15) 
and keratinocyte-specific transcripts (e.g., BNC1, DSC3, and DSG3) This, in addition to our careful histologic 
re-review of all samples, supports the correct diagnosis of  these tumors as squamous malignancies.
We next performed hierarchical clustering using dynamic genes quantified in these ESCC primaries, 
showing 3 distinct subtypes of  SSA ESCC. Gene set analysis of  the subtypes revealed differences most 
prominently in their expression of  markers for neural differentiation, morphogenesis, and DNA repair and 
metabolism (Figure 4 and Supplemental Figures 2–5). We performed this analysis independently on 2 split 
subgroups of  the samples, and saw evidence for these subtypes in both analyses, suggesting that this finding 
is robust. Subtype 1 could further be divided into 2 subgroups (1a and 1b) of  nearly equal size (18 and 15 
samples, respectively), which differed further in expression of  transcripts associated with DNA replica-
tion and repair, small GTPases, and homeobox genes (e.g., HOXA11/C11 and SIX1/4). Silhouette width 
analysis and principal component analysis also supported the existence of  3 distinct subtypes of  SSA ESCC 
Figure 3. Mutational analysis of exome data and p53. Signature stability (top) and mutational signatures (bottom) are shown for Malawian (A) and 
Chinese (B) exome analyses. Stability is a measure of the reproducibility of a signature and reconstruction error is a measure of the reproducibility of the 
original mutation catalog (25). In Chinese patients, 2 signatures (aging and apolipoprotein B mRNA editing enzyme catalytic polypeptide-like [APOBEC]) 
are noted, whereas in Malawian esophageal squamous cell carcinoma (ESCC), a third signature is also identified, characterized by cytosine to adenine 
transversions and cytosine to thymine transitions.
based on RNA expression (Supplemental Figures 6 and 7). Patients of  subgroup 1b were more likely to be 
smokers, more likely to be male, more likely to report use of  wood-burning cooking methods, less likely to 
report use of  more refined white corn flour, and were older (Figure 1).
We searched for defining features of  these potentially novel subtypes. Subgroup 1b was more quiet 
genomically, with the fewest somatic mutations per Mb (0.75) compared with subgroup 1a (11.85) and 
subtype 2 (3.71) (Figure 1). Subgroup 1b also demonstrated fewer CNAs (Figure 2), most notably with 
fewer amplifications of  MYC, EGFR, and TP63 and fewer deletions of  CDKN2A/B compared with other 
subgroups. Along with these differences in genomic complexity, subgroup 1b also was significantly less 
likely to exhibit TP53 mutation (P < 0.05, ANOVA), in accord with p53’s known role in regulating DNA 
Figure 4. RNA expression analysis of Malawian esophageal squamous cell carcinoma (ESCC) tumors. A heat map of transcripts identified as being 
dynamically expressed (red, upregulated transcripts; blue, downregulated transcripts) among the 59 patient samples. Unsupervised hierarchical cluster-
ing suggests 2 subtypes (1 and 2) with significantly different expression profiles. Subtype 1 can be further divided into 2 subtypes (1a and 1b) that are 
distinguished by frequency of copy number alterations (CNAs), point mutations, and TP53 mutations (Figures 1 and 2). The finding of 3 subtypes by RNA 
expression analysis is consistent with silhouette width and principal component analysis (Supplemental Figures 6 and 7).
repair and ploidy. Mutations of  a few other genes (e.g., MUC2, SERPINB4) appeared to be enriched in spe-
cific subtypes, but given our total sample size, our study was underpowered to characterize the molecular 
landscapes of  each subtype. In aggregate, these observations support the existence of  3 distinct molecular 
subtypes of  SSA ESCC that differ in clinical features, genomic complexity, p53 mutational status, and 
RNA expression.
Discussion
In this work, we performed integrated genomic analysis of  SSA ESCC. This includes dedicated, unbi-
ased analyses for somatic DNA mutations of  the exome, CNAs, RNA expression profiling, potentially 
novel mutagenic signatures, and occult pathogens. Our work has shown that in molecular terms, the 
genomic events (driver activation and tumor suppressor gene loss) that cause ESCC in Malawi appear to 
be similar to those in the Western countries Japan and China. Our data also suggest, however, that the 
mechanism of  mutagenesis, that is, the epidemiologic cause of  this highly common cancer, is likely dif-
ferent between ESCC in SSA versus ESCC in other parts of  the world. Moreover, we identified evidence 
for 3 distinct subtypes of  SSA ESCC based on RNA expression, CNAs, and point mutation frequency. 
Finally, perhaps surprisingly given the important role of  viral pathogens in the other most common can-
cers of  SSA (e.g., Kaposi’s sarcoma, cervical cancer, and Burkitt’s lymphoma), we did not find evidence 
for a viral cause of  SSA ESCC.
The finding of  discrete ESCC subtypes based on RNA expression and CNA analysis was unexpected. 
This observation is not explained by available differences in tumor content, grade, or stromal contamina-
tion (Figure 1), and subtypes 1 and 2 were identified when the tumors were analyzed in 2 discrete cohorts 
prior to the aggregate analysis shown in Figure 4. Tumors of  all the distinct subtypes clustered together 
when compared with other PanCan malignancies (Supplemental Figure 1) and appeared as similar clas-
sically squamous cancers by routine histopathological examination, although we think it is likely that at 
least subtypes 1 and 2 could be discerned using immunohistochemical markers. Subgroups 1a and 1b were 
distinguished by the frequency of  CNAs, mutations per Mb sequenced, and frequency of  TP53 and TP63 
alterations (Figures 1 and 2). The subtypes were additionally distinguished by gene set analysis, with sub-
group 1a showing a relative overexpression of  DNA replication, repair, and recombination markers. In 
other studies, these transcripts are often associated with specific periods of  the cell cycle (e.g., S-phase), 
suggesting that this subgroup may cycle more rapidly than other subtypes. Subgroup 1b demonstrated a 
relative underexpression of  homeobox genes, and subtype 2 was characterized by increased expression 
of  transcripts associated with neural differentiation (Figure 4). It is unclear if  these ESCC subtypes are 
restricted to SSA, or are present in esophageal cancers of  other regions.
Several lines of  evidence suggest that an unrecognized, occult carcinogen accounts for the epidemic 
of  ESCC in SSA. First, tobacco use does not explain ESCC in SSA. Prior epidemiological studies have 
demonstrated that tobacco use is not a likely cause of  most ESCC in SSA (6), and other classic smoking-
associated cancers (e.g., bladder, lung, non-HPV head and neck) are not common in SSA. In our cohort, 
the majority of  patients did not use tobacco, either smoked or chewed, and we did not see evidence for the 
known mutational spectrum of  inhaled tobacco in the somatic tumor exomes. Likewise, our data exclude 
an integrated or episomal virus as a cause of  SSA ESCC. In contrast, we did observe a mutational signature 
in our sample that is similar to an unusual signature that has been previously reported in a handful of  cases 
(signature 29, COSMIC) (29). To date, this signature has been observed in only 4 Western patients with 
oropharyngeal squamous cell carcinoma, but was present in a substantial fraction of  Malawian patients. In 
aggregate, we believe this analysis suggests an occult environmental agent, which is not inhaled tobacco or 
HPV, that substantially contributes to ESCC in Malawi. Since there are 100,000s of  cases of  ESCC in SSA 
annually, and the population of  this region is rapidly growing, this undetermined carcinogen is of  consider-
able importance from a global public health perspective.
Effectively treating or palliating the extremely high burden of  ESCC poses a major challenge to health 
systems throughout SSA, especially given limited radiotherapy, endoscopy, and thoracic surgery capabili-
ties. Moreover, prevention efforts are considerably hampered by poor understanding of  why the incidence 
of  ESCC is so high in the region. Applying modern molecular approaches to ESCC and other cancers can 
complement classical epidemiologic studies, by helping support or disprove possible etiologic contribu-
tors, and ultimately informing population-level strategies to prevent this almost uniformly fatal cancer in 
SSA when it occurs. Therapeutic targets might also be suggested in a region where poor supportive care 
environments limit the utility of  conventional radiotherapy and cytotoxic chemotherapy to treat cancer. 
As in our work reported here, it is vital that the global oncology community continue to partner with SSA 
colleagues to apply modern molecular techniques to cancer research in the region, in a manner that ben-
efits local individuals and populations.
Methods
Clinical/collection. From January 2011 to February 2013, informed consent was obtained from patients 
with suspected ESCC undergoing diagnostic upper endoscopy at 2 national teaching hospitals in Lilon-
gwe or Blantyre. A study questionnaire and medical record review was conducted to obtain demographic 
details and risk factor data. Endoscopic biopsies obtained using forceps were divided into 2 formalin-fixed 
paraffin-embedded specimens for local histologic interpretation, and 1 research specimen that was frozen 
at –80°C. Paired whole blood (60 ml) was collected in EDTA and centrifuged for buffy coat isolation and 
freezing at –80°C.
Whole-exome sequencing. Genomic DNA was extracted by using a QIAGEN DNA/RNA kit and then 
sheared to a peak target size of  300 bp using a Covaris Focused-ultrasonicator. The DNA library was pre-
pared and captured using the SureSelect XT Human All Exon V5 according to the manufacturer’s proto-
cols, and then sequenced by an Illumina HiSeq2000 with 100-bp paired-end reads.
DNA reads were aligned to the human hg19 genome assembly using BWA (37). After mapping, 
marking duplicates, local realignment around indels, and base quality score recalibration were per-
formed by using the GATK tool kit (38). Combined analysis by using UNCeqR (22) and MuTect (39) 
was done to detect somatic nucleotide variations. Circular binary segmentation (CBS) and GISTIC (40) 
were used for somatic CNA analysis. Gene mutational signatures analysis was performed using the 
WTSI Mutational Signature Framework (26, 27), and the Chinese ESCC data set (15) was included and 
analyzed for comparison.
RNA sequencing. RNA was extracted and rRNA was removed by using the Ribo-Zero kit (Illumina). 
RNA libraries were prepared by using the Illumina TruSeq RNA Sample Preparation Kit v2 and then 
sequenced by the Illumina HiSeq2000. Reads were subjected to quality control as previously described 
(23). RNA reads were aligned to the human hg19 genome assembly using Mapsplice (41). Gene expression 
was quantified using RSEM (42) and within-sample normalized to a fixed upper quartile of  total reads. All 
data were log2 transformed, median centered, and clustered using ConsensusClusterPlus (43). The opti-
mal number of  RNA expression subgroups was initially determined using silhouette width and principal 
component analysis. The classification to nearest centroids (ClaNC) (44) prediction method was used to 
robustly identify smaller gene sets differentially expressed between groups. Further gene set analysis was 
then performed using significance analysis of  microarrays for sequencing (SAMSeq) (45). Heat maps were 
generated using Java TreeView (46).
Viral sequence detection. To detect viral sequences, RNA reads were first aligned to the human hg19 
genome assembly. Unaligned sequences were processed by aligning to all viral sequences from the NCBI 
viral genome database and assembled by using Triniby (47). To search for possible unknown HPV strains in 
RNA reads, additional steps of  aligning to all known HPV strains with relaxed mapping criteria were per-
formed. All the sequences that share 70% similarity with any known HPV strains were manually checked 
against other possible alignments.
Data availability. To comply with restrictions on sequencing data put in place by the Malawi National 
Health Sciences Research Committee, the genomic data have been securely stored at the University of  
North Carolina. Data will be made available upon request to qualified investigators with approval from the 
Malawi National Health Sciences Research Committee.
Statistics. Statistical analyses were performed in each bioinformatic method as described by the relevant 
citation. RNA transcripts were log2 transformed and median centered before clustering. Differences among 
clinical and environmental characteristics, single-nucleotide polymorphisms, and CNAs between subtypes 
were calculated by ANOVA. A P value of  less than 0.05 was considered significant.
Study approval. Patients over 18 years of  age and willing to participate in this study provided written 
informed consent in their native language. Human studies approval was given by the Malawi National 
Health Sciences Research Committee, Lilongwe, Malawi and the University of  North Carolina Internal 
Review Board, Chapel Hill, North Carolina.
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